
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first isolated from rabbit brain in 1977, named for its ability to promote slow-wave (delta) sleep. Research has since revealed a broader profile including stress-hormone modulation, neuroendocrine regulation, and potential applications in substance withdrawal. DSIP is not FDA-approved. This is not medical advice.
Quick Reference: Standard Protocol
| Parameter |
Standard Protocol |
| Dose |
250 mcg |
| Route |
Subcutaneous injection |
| Timing |
1-3 hours before bed |
| Frequency |
5 days on, 2 days off |
| Cycle |
8 weeks on, 8 weeks off |
| Vial size |
5 mg |
| Reconstitution |
2 mL bacteriostatic water → 2,500 mcg/mL |
| Draw amount |
10 units on insulin syringe |
| Storage |
Refrigerate 2-8°C, use within 28 days |
Standard protocol: 250 mcg subcutaneous, 1-3 hours before bed, 5 days on / 2 days off, for 8-week cycles.
For the full DSIP peptide profile, see our DSIP peptide page.
Cycling: 8 Weeks On, 8 Weeks Off
Run 250 mcg nightly (5 on / 2 off) for 8 weeks, then take 8 weeks off. DSIP's documented delayed effects -- where sleep improvements persist beyond the active dosing period -- mean the off-cycle period is often still beneficial.
While no clinical evidence demonstrates DSIP tolerance development, cycling maintains receptor sensitivity and allows you to monitor residual effects during the off period.
Some practitioners reference alternative cycling patterns:
Dr. Seeds protocol: 100 mcg subcutaneously at night, administered daily, every 3 days, or weekly depending on individual response.
Pulse protocol: 100-200 mcg nightly for 10 consecutive days, followed by 20 days off. This leverages DSIP's delayed effects where improvements persist beyond active dosing.
The 250 mcg / 5-on / 2-off standard from the cheat sheet is the recommended starting point. These alternatives reflect community variations.
Routes of Administration
Subcutaneous injection (standard): Inject into abdominal area (2+ inches from navel), thigh, or upper arm. Use 29-31 gauge insulin syringe. Rotate injection sites.
Clinical context: Early studies used IV infusions at 25 nmol/kg with morning timing and still observed delayed sleep benefits, but evening SC injection is the community standard.
Reconstitution Quick Reference
| Vial Size |
BAC Water |
Concentration |
250 mcg Dose |
| 5 mg |
2 mL |
2,500 mcg/mL |
10 units |
Math: 5,000 mcg / 2 mL = 2,500 mcg/mL. For 250 mcg: 250 / 2,500 = 0.1 mL = 10 units. One vial lasts 20 doses.
Swirl gently -- do not shake. Refrigerate at 2-8°C and use within 28 days. For step-by-step instructions, see the Reconstitution Calculator.

Where These Numbers Come From
DSIP's research spans over 40 years, though many studies are small-scale by modern standards.
Sleep studies: Schneider-Helmert (1981) administered 25 nmol/kg IV to healthy volunteers and observed enhanced delta sleep with delayed onset of effects. A 1992 double-blind study in 16 chronic insomnia patients found improved subjective sleep quality vs placebo (PMID: 1299794).
Stress and withdrawal: DSIP attenuates basal and stress-induced ACTH release, dampening the cortisol stress response. Dick et al. (1984) successfully treated withdrawal symptoms in opiate- and alcohol-dependent patients (PMID: 6548969).
Safety profile: Pollard & Pomfrett (2001) described DSIP as "incredibly safe" in a comprehensive review -- no lethal dose identified in animal studies, no significant adverse effects beyond transient headache, nausea, and vertigo in humans.
Neuroprotection: A 2021 study showed DSIP accelerated motor function recovery in rats following focal stroke, suggesting applications beyond sleep.
Stacking Protocols
| Stack |
Components |
Purpose |
| Anxiolytic Sleep |
DSIP 250 mcg + Selank 200-400 mcg intranasal |
Delta sleep + GABA-modulatory anxiolysis |
| Sleep + Longevity |
DSIP 250 mcg + Epitalon 2 mg |
Delta wave promotion + pineal melatonin |
| Sleep + Recovery |
DSIP 250 mcg + Ipamorelin 100-200 mcg |
Deep sleep + GH release during sleep |
Inject stacked peptides at separate sites. Do not mix in the same syringe unless validated for compatibility.
Side Effects & Safety
- Transient headache -- the most commonly reported side effect
- Mild nausea -- usually resolves within 30 minutes
- Temporary dizziness/vertigo -- reported at higher doses
- Injection site redness -- standard for SC peptides
- No lethal dose identified in animal studies
- No dependency or withdrawal documented
- No respiratory depression -- unlike pharmaceutical sleep aids
DSIP appears on the FDA's list of bulk drug substances with potential safety concerns, reflecting regulatory conservatism around limited human data rather than documented toxicity.
Frequently Asked Questions
What is the standard DSIP dose?
250 mcg subcutaneously, 1-3 hours before bed, 5 days on / 2 days off, cycled 8 weeks on / 8 weeks off. Use a 5 mg vial with 2 mL BAC water -- 250 mcg equals 10 units.
How long does it take for DSIP to work?
Many users report improved sleep within 1-3 nights. Cumulative effects on sleep architecture may take 5-10 days of consistent use.
Can DSIP be used every day?
The standard protocol uses 5 days on / 2 days off. Short-term daily use (10-30 days) appears in some community protocols, but 5 on / 2 off maintains receptor sensitivity.
What is the best time to take DSIP?
1-3 hours before intended sleep. DSIP appears to prime sleep-regulatory circuits rather than acting as an acute sedative.
Does DSIP cause dependency or withdrawal?
No dependency or withdrawal documented. DSIP has itself been studied for treating opiate and alcohol withdrawal symptoms.
Is DSIP FDA-approved?
No. DSIP is a research peptide with no approved human indication.
References
| Citation |
Topic |
PMID |
| Graf & Kastin, Neurosci Biobehav Rev (1984) |
DSIP comprehensive review |
6145137 |
| Schneider-Helmert et al., Int J Clin Pharmacol Ther Toxicol (1981) |
Delta sleep enhancement in healthy volunteers |
6895513 |
| Schneider-Helmert, Neuropsychobiology (1992) |
Double-blind insomnia study |
1299794 |
| Dick et al., Eur Neurol (1984) |
Withdrawal syndrome treatment |
6548969 |
| Schneider-Helmert, Eur Neurol (1984) |
DSIP in narcolepsy |
6548968 |
For educational and research purposes only. This is not medical advice. DSIP is a research peptide not approved by the FDA for human use.